Article Detail - JE Part B
Billing and Coding: MolDX: Circulating Tumor Cell Marker Assays Retirement - Effective July 28, 2021
This coverage article has been retired under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).
Effective Date: July 28, 2021
Summary: Coverage articles may be retired due to lack of evidence of current problems or CMS may have issued guidance regarding national coverage. The Noridian guidance in the retired article may still be helpful in assessing medical necessity. Where providers have adjusted their billing and coding practices to correspond to the guidance in a coverage article, they will want to be very careful in departing from these practices just because the article is retired. Provider offices remain responsible for correct performance, coding, billing, and medical necessity under Medicare. This responsibility for correct claims submission is unchanged whether or not there is a coverage article in place.
This article is being retired because the information in this article has been incorporated within the new Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells article.
Visit the Noridian Medicare Coverage Articles webpage to access the Retired articles in the CMS MCD.
Last Updated Mon, 09 Aug 2021 17:58:25 +0000